S&P 500   3,137.35 (+0.04%)
DOW   27,914.03 (+0.02%)
QQQ   204.45 (+0.19%)
AAPL   269.52 (+0.97%)
FB   201.01 (-0.16%)
MSFT   151.52 (+0.11%)
GOOGL   1,345.04 (+0.15%)
AMZN   1,742.08 (-0.42%)
CGC   20.12 (-5.50%)
NVDA   215.00 (+1.33%)
MU   47.76 (+2.82%)
BABA   201.31 (+1.29%)
GE   11.00 (+0.09%)
TSLA   349.62 (+2.97%)
AMD   39.65 (+1.85%)
F   9.08 (+0.78%)
PRI   135.36 (+0.00%)
NFLX   297.90 (-1.52%)
BAC   33.51 (+0.00%)
GILD   66.97 (+0.04%)
DIS   146.58 (+0.25%)
S&P 500   3,137.35 (+0.04%)
DOW   27,914.03 (+0.02%)
QQQ   204.45 (+0.19%)
AAPL   269.52 (+0.97%)
FB   201.01 (-0.16%)
MSFT   151.52 (+0.11%)
GOOGL   1,345.04 (+0.15%)
AMZN   1,742.08 (-0.42%)
CGC   20.12 (-5.50%)
NVDA   215.00 (+1.33%)
MU   47.76 (+2.82%)
BABA   201.31 (+1.29%)
GE   11.00 (+0.09%)
TSLA   349.62 (+2.97%)
AMD   39.65 (+1.85%)
F   9.08 (+0.78%)
PRI   135.36 (+0.00%)
NFLX   297.90 (-1.52%)
BAC   33.51 (+0.00%)
GILD   66.97 (+0.04%)
DIS   146.58 (+0.25%)
S&P 500   3,137.35 (+0.04%)
DOW   27,914.03 (+0.02%)
QQQ   204.45 (+0.19%)
AAPL   269.52 (+0.97%)
FB   201.01 (-0.16%)
MSFT   151.52 (+0.11%)
GOOGL   1,345.04 (+0.15%)
AMZN   1,742.08 (-0.42%)
CGC   20.12 (-5.50%)
NVDA   215.00 (+1.33%)
MU   47.76 (+2.82%)
BABA   201.31 (+1.29%)
GE   11.00 (+0.09%)
TSLA   349.62 (+2.97%)
AMD   39.65 (+1.85%)
F   9.08 (+0.78%)
PRI   135.36 (+0.00%)
NFLX   297.90 (-1.52%)
BAC   33.51 (+0.00%)
GILD   66.97 (+0.04%)
DIS   146.58 (+0.25%)
S&P 500   3,137.35 (+0.04%)
DOW   27,914.03 (+0.02%)
QQQ   204.45 (+0.19%)
AAPL   269.52 (+0.97%)
FB   201.01 (-0.16%)
MSFT   151.52 (+0.11%)
GOOGL   1,345.04 (+0.15%)
AMZN   1,742.08 (-0.42%)
CGC   20.12 (-5.50%)
NVDA   215.00 (+1.33%)
MU   47.76 (+2.82%)
BABA   201.31 (+1.29%)
GE   11.00 (+0.09%)
TSLA   349.62 (+2.97%)
AMD   39.65 (+1.85%)
F   9.08 (+0.78%)
PRI   135.36 (+0.00%)
NFLX   297.90 (-1.52%)
BAC   33.51 (+0.00%)
GILD   66.97 (+0.04%)
DIS   146.58 (+0.25%)
Log in

NASDAQ:HGSI - Human Genome Sciences Stock Price, Forecast & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Add
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
VolumeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Human Genome Sciences, Inc (HGS) is a biopharmaceutical company. The Company's products include BENLYSTA (belimumab) for systemic lupus erythematosus (SLE) and raxibacumab for inhalation anthrax. HGS continues to deliver raxibacumab to the United States Strategic National Stockpile (SNS) for emergency use in treating inhalation anthrax. In addition to the Company's internal pipeline, it has financial rights to two drugs that GlaxoSmithKline (GSK) has advanced to late-stage development. Read More…

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorN/A
Current SymbolNASDAQ:HGSI
CUSIPN/A
Phone+1-301-3098504

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable

Receive HGSI News and Ratings via Email

Sign-up to receive the latest news and ratings for HGSI and its competitors with MarketBeat's FREE daily newsletter.


Human Genome Sciences (NASDAQ:HGSI) Frequently Asked Questions

What is Human Genome Sciences' stock symbol?

Human Genome Sciences trades on the NASDAQ under the ticker symbol "HGSI."

Has Human Genome Sciences been receiving favorable news coverage?

Media headlines about HGSI stock have trended somewhat positive this week, InfoTrie reports. InfoTrie identifies negative and positive news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Human Genome Sciences earned a news impact score of 1.2 on InfoTrie's scale. They also assigned headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near future. View News Stories for Human Genome Sciences.

What other stocks do shareholders of Human Genome Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Human Genome Sciences investors own include Bank of America (BAC), Jazz Pharmaceuticals (JAZZ), InterMune (ITMN), Intel (INTC), Alphabet (GOOG), First Solar (FSLR), Finisar (FNSR), Changyou.Com (CYOU), Cisco Systems (CSCO) and Advanced Micro Devices (AMD).

What is Human Genome Sciences' official website?

The official website for Human Genome Sciences is http://www.hgsi.com/.

How can I contact Human Genome Sciences?

Human Genome Sciences' mailing address is 14200 Shady Grove Rd, ROCKVILLE, MD 20850-7464, United States. The biopharmaceutical company can be reached via phone at +1-301-3098504.


MarketBeat Community Rating for Human Genome Sciences (NASDAQ HGSI)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  131 (Vote Outperform)
Underperform Votes:  145 (Vote Underperform)
Total Votes:  276
MarketBeat's community ratings are surveys of what our community members think about Human Genome Sciences and other stocks. Vote "Outperform" if you believe HGSI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HGSI will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/10/2019 by MarketBeat.com Staff

Featured Article: What is Blockchain?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel